Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oyster Point Pharma, Inc. (OYST)
|
Add to portfolio |
|
|
|
| Price: |
$16.60
| | Metrics |
| OS: |
26.8
|
M
| |
|
|
| Market cap: |
$446
|
M
| |
-361
|
% ROIC
|
|
Net debt:
|
$22.5
|
M
| |
|
|
|
EV:
|
$468
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($158)
|
M
| |
|
|
|
EBIT
|
($158)
|
M
| |
|
|
| EPS |
($6.65)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 |
| Revenues | 24.5 | 0.0 | 0.0 | 0.0 | 13.8 | 3.6 |
| Revenue growth | | | | -100.0% | | |
| Cost of goods sold | 1.5 | 0.0 | 0.0 | 0.0 | 16.7 | 5.7 |
| Gross profit | 23.0 | 0.0 | 0.0 | 0.0 | -3.0 | -2.1 |
| Gross margin | 93.8% | | | | -21.7% | -56.5% |
| Sales and marketing | 54.6 | 9.9 | | | | |
| Research and development | 24.2 | 39.8 | 33.6 | 13.8 | | |
| General and administrative | 40.8 | 21.3 | 13.7 | 3.0 | 3.0 | 2.1 |
| EBIT | -96.7 | -71.0 | -47.3 | -16.7 | -16.7 | -5.7 |
| EBIT margin | -393.9% | | | | -121.7% | -156.5% |
| Pre-tax income | -100.7 | -70.5 | -45.7 | -16.5 | 0.0 | -19.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -100.7 | -70.5 | -45.7 | -16.5 | 0.0 | -19.1 |
| Net margin | -410.2% | | | | 0.0% | -527.1% |
| |
| Diluted EPS | ($3.87) | ($2.92) | ($9.97) | ($11.69) | $0.00 | ($13.56) |
| Shares outstanding (diluted) | 26.0 | 24.1 | 4.6 | 1.4 | 1,412.0 | 1.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|